Cabaletta Bio, Inc. (CABA)
Chart Events
Performance Outlook
| Previous Close | 10.39 |
| Open | 10.39 |
| Bid | 9.31 x 800 |
| Ask | 11.01 x 1000 |
| Day's Range | 9.31 - 10.81 |
| 52 Week Range | 5.51 - 16.38 |
| Volume | 186,822 |
| Avg. Volume | 123,732 |
| Market Cap | 259.799M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -10.97 |
| Earnings Date | Nov 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.33 |
Fair Value
Related Research
- Simply Wall St.
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- GlobeNewswire
Cabaletta Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021 at 5:20 p.m. ET. A live webcast of the presentation will be available on the News and Events section of the company’s website at www.cabalettabio.com. Following the presentation, a replay of the webcast will be available on the website for 90 days.About Cabaletta Bio Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.Contacts: Anup Marda Chief Financial Officer investors@cabalettabio.comSarah McCabe Stern Investor Relations, Inc. 212-362-1200 sarah.mccabe@sternir.com
- GlobeNewswire
Cabaletta Bio to Participate in Upcoming January Investor Conferences
PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in January: * H.C. Wainwright Virtual BioConnect Conference on Monday, January 11, 2021: A pre-recorded fireside chat with Dr. Nichtberger will be available on the company’s website at 6:00 a.m. ET. * Stern Investor Relations Corporate Access Event on Monday, January 11, 2021: A pre-recorded fireside chat with Dr. Nichtberger will be available on the company’s website at 7:00 a.m. ET.All webcasts of presentations are available on the News and Events section of the company’s website at www.cabalettabio.com. Following the presentations, a replay of the webcasts will be available on the website for 90 days.About Cabaletta Bio Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.Contacts: Anup Marda Chief Financial Officer investors@cabalettabio.comSarah McCabe Stern Investor Relations, Inc. 212-362-1200 sarah.mccabe@sternir.com
